Deep cervical lymph nodes of patients with multiple sclerosis show dysregulated B cells in the presence of Epstein-Barr virus

3 Authors:

- 4 Joona Sarkkinen^{1,*,†}, Dawit Yohannes^{1,†}, Nea Kreivi¹, Pia Dürnsteiner¹, Jani
- 5 Huuhtanen¹⁻⁴, Kirsten Nowlan¹, Goran Kurdo⁵, Riikka Linden⁵, Mika Saarela⁶, Pentti J
- 6 Tienari^{1,6}, Eliisa Kekäläinen¹, Maria Perdomo⁷, Sini M Laakso^{1,6,*}
- 7

8 Affiliations:

- 9 ¹ Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
- ¹⁰ ² Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki
- 11 and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
- 12 ³ ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki
- 13 University Hospital Comprehensive Cancer Center, Helsinki, Finland
- ⁴ Department of Computer Science, Aalto University School of Science, Espoo, Finland
- ¹⁵ ⁵ Department of Radiology, University of Helsinki and Helsinki University Hospital,
- 16 Helsinki, Finland
- ⁶ Department of Neurology, Brain Center, Helsinki University Hospital, Helsinki, Finland
- ¹⁸ ⁷ Department of Virology, University of Helsinki and Helsinki University Hospital,
- 19 Helsinki, Finland
- 20 [†] Equal contribution
- 21 * Corresponding author
- 22

23 Abstract: Despite the recognized role of Epstein-Barr virus (EBV) in predisposing to 24 multiple sclerosis (MS) and the effectiveness of B cell-depleting therapies in MS, the 25 mechanism of autoimmunity remains elusive. Using fine needle aspirations, we investigated deep cervical lymph nodes (dcLNs), the primary site of the adaptive 26 27 immune response against EBV, in newly diagnosed untreated MS patients and healthy 28 controls. We characterized the immune landscape of dcLNs with scRNAseg and CITE-29 seq and observed increased memory B cell proportions and reduced germinal center 30 (GC) B cells with decreased clonality in patients with MS compared to healthy controls. 31 In the patient with an active MS relapse, we detected elevated plasmablasts, reduced GC B cells, and clonally expanded memory CD8 T cells targeting EBV in the dcLN. 32 33 These findings, along with increased EBV DNA detection in dcLNs and viral loads in 34 patient saliva, support B cell dysregulation as a key mechanism in MS pathogenesis. 35

37 INTRODUCTION

38 Multiple sclerosis (MS) is the most common neurological autoimmune disease affecting

39 2.8 million individuals worldwide and has an increasing prevalence (1). Demyelinating

40 inflammatory lesions of the central nervous system (CNS) are the cause of clinical

41 attacks in relapsing-remitting MS (RRMS), which presents in 90% of patients, and

42 migration of lymphocytes to the CNS is the hallmark of the disease pathology (2).

43 Despite research efforts, the exact mechanisms that lead to MS remain unknown.

44

45 Several environmental and genetic risk factors that predispose to MS have been

46 observed, of which Epstein Barr Virus (EBV) infection in early adulthood is by far the

47 most significant. EBV infection is characterized by the proliferation and transformation of

48 infected B cells and the subsequent proliferation of CD8+ T cells targeting EBV. After

49 primary infection, EBV persists lifelong in a small subset of B cells (3). Close to 100% of

50 MS patients are EBV seropositive (4, 5), and recently, Bjornevik et al showed that EBV

51 infection in early adulthood raises the risk for MS by 32-fold (6). These epidemiological

52 findings were limited only to EBV, and seropositivity to other herpesviruses such as

53 cytomegalovirus (CMV) does not raise the risk for MS.

54

Antibodies recognizing EBV may cross-react with self-antigens (7). Recently, clonally expanded intrathecal plasmablasts (PBs) were found to produce antibodies that bind to EBV transcription factor EBNA1 but also to glial cell adhesion molecule (GlialCAM). In addition, EBNA1 immunization of experimental autoimmune encephalitis (EAE) mice exacerbated the EAE by increasing autoreactive B and T cell responses. (8) EBVtargeting cytotoxic CD8+ T cells have also been detected in autopsy samples of demyelinating brain lesions of MS patients. (9, 10)

63 The adaptive immune response against EBV occurs most importantly in the deep

64 cervical lymph nodes (dcLN) (11), which drain CNS lymphatics carrying neuronal

65 autoantigens also in MS patients (12–14). Interestingly, dcLNs are enlarged in MS

66 patients compared to healthy individuals (15), and clonally expanded B cells extracted

67 from the demyelinating lesions in MS patients commonly derive from the dcLNs (16).

Therefore, it is plausible that dcLN could be the original site where MS pathogenesis isinitiated.

70

71 These findings, together with the high efficacy of B cell-depleting therapies in treating 72 RRMS, have moved the MS research focus from T cells towards B cells and T-B cell 73 crosstalk. B cell responses are refined in germinal centers (GCs), where B cell somatic 74 hypermutations (SHMs) and class switching take place. GCs are typically found in secondary lymphoid tissues, such as LNs. Ectopic GCs, which develop in response to 75 76 chronic inflammation (17), have also been found on the meninges of MS patients 77 possibly contributing to B cell autoreactivity in MS (16, 18). The GC reaction is regulated 78 by Tfr cells, whereas Tfh cells supply aid to developing B cells, which differentiate into 79 memory B cells (MBCs) and high-affinity antibody (ab) producing PBs and plasma cells 80 (PCs) (19). The ratio of follicular T helper cells (Tfh) to follicular regulator cells (Tfr) in 81 the circulation has been reported to be increased in MS and to correlate with intrathecal 82 IgG production, which suggests dysregulation of GC reactions (20). 83 84 We hypothesized that EBV infection disrupts B cell homeostasis and the GC 85 microenvironment in the dcLNs of MS patients, creating the ground for B cell-mediated 86 autoimmunity. Using fine needle aspirations (FNAs) of the dcLNs (21) in newly 87 diagnosed MS patients and healthy controls, we investigated the immunological

88 landscape of dcLNs at single-cell resolution focusing on the GC reaction. We show, for

89 the first time in an *ex vivo* analysis of MS patients, an intranodal expansion of memory B

90 cells and diminished GC B cell proportion and clonality, paralleled by EBV detection.

91 Our results reveal altered cellular composition of dcLNs in newly diagnosed MS

92 patients, providing insights into the role of EBV in disease pathogenesis and to the

93 efficacy of B cell depleting therapies in RRMS.

94

96 **RESULTS**

97 Investigation of deep cervical lymph nodes accessed by fine needle aspirations

98 Ultrasound-guided FNAs of dcLNs followed by isolation of viable single cells and 99 immediate processing for 5' single-cell RNA sequencing including T and B cell receptor 100 sequencing were performed on 7 MS patients (mean age 36 years, 4/9 females) and 6 101 healthy controls (mean age 28 years, 3/5 females, Fig. 1A). The width and height of 102 dcLNs, measured with ultrasound, did not differ between MS patients and controls 103 (median 0.53 vs 0.49 cm, t-test p = 0.7024; median 1.85 vs 1.26 cm, t-test p = 0.1673, 104 respectively). Hybrid-capture sequencing of DNA viruses (22) was performed on dcLN 105 FNAs, and blood and saliva were collected for further viral assays. Clinical features of 106 MS patients, including the Expanded Disability Status Scale (EDSS), are shown in 107 Table 1, and further information on study subjects and assays is presented in Data file 108 S1.

109

110 After excluding samples with an abnormally low number of cells due to reported technical 111 issues in 10x runs, scRNA-seq data from six MS patients and three healthy controls 112 containing a total of 73,074 cells, with an average of 8,195 cells per MS patient and 7,968 113 cells for the controls, were taken for further analysis. All cells were merged for combined 114 cluster analysis in Seurat (23), and the resulting clusters contained cells from each 115 sample without evident batch effect (Fig. 1B). We compared also cell clusters between 116 the batches (Data file S1) and observed that resulting clusters were well aligned across 117 library preparation and sequencing batches showing no specific batch effect (see 118 Methods and Fig. S1A-E) (24). We performed cell type determination using a combination 119 of automatic annotation with SingleR (25) using the Monaco reference (26) and manual 120 annotation aided by the CITE-seq data that we had for 4/6 MS patients and all (3/3) 121 healthy controls (Fig. 1C). Manual cell type determination was used especially for T and 122 B cell subsets using a combination of key markers on both transcript and protein levels 123 (Fig. 1D-E, Data file S2-3, see Supplementary Material for details). Most of the dcLN cells 124 were either T or B cells, whereas natural killer (NK) cell and myeloid cell subsets 125 accounted for less than 5% of all identified cells (Fig. 1F).

127 Two Tfh clusters were identified and characterized by canonical CXCR5 expression (27). 128 of which the other cluster was in the minority ($\approx 0.5\%$ of all cells). Given the abundant 129 expression of BCL6 (28), ICOS (29), TOX2 (30), PDCD1 (31), SH2D1A (SAP) (32), and 130 IL21 (33), this smaller cluster likely represents a more active phenotype of Tfh (here GC 131 Tfh) cells interacting with GC B cells (34) (Fig. 1D, Data file S2). Instead, the other Tfh 132 cluster, which was the second most prevalent of all cells (≈ 11%) after naïve CD4+ T cells 133 (\approx 40%, Fig. 1F), could reside outside the GC given the lower *BCL6* expression (34, 35) 134 and was annotated as Tfh-like cells (Fig. 1D).

Increased proportion of memory B cells and decreased GC B cells and GC Tfh cells in dcLNs of MS patients

137 We noted a significantly increased proportion of memory and a marginally elevated 138 proportion of naïve B cells in MS patients compared to healthy controls (unpaired t-test p 139 = 0.042 and log2 fold change (log2fc) = 0.88 for memory B cells; p = 0.064, log2fc = 0.75 140 for naïve B cells, Fig. 1G, Data file S4). Next, we pooled all cells by subject group and 141 compared the overall cell type frequency distribution between MS patients and healthy 142 controls. The cell type frequencies, representing cellular compositions in dcLNs, were 143 significantly different between MS patients and controls (Pearson's Chi-squared test, p-144 value < 2.2e-16). Furthermore, evaluation of the standardized Pearson residuals 145 suggests that in addition to memory and naïve B cells, PBs and Tfh-like cells were 146 significantly increased while naïve and intermediate CD4s, GC B cells, naïve CD8s, and 147 GC Tfh cells were significantly decreased in MS patients compared to healthy controls 148 (Fig. 1H, each having extreme standardized Pearson residual values above ±3.65, 149 corresponding to Bonferroni corrected p-values < 0.00013 in the null distribution of the 150 standardized residuals). Tfr cells, which share transcriptional properties with Treg and Tfh 151 cells and differentially expressed FOXP3. IKZF2. CTLA4 on transcript level and PDCD1. 152 and ICOS on both transcript and protein level (19, 36) (Data file S2-3), did not differ 153 between MS patients and healthy controls. Decreased GC B cells and GC Tfh cells 154 combined with a simultaneous expansion of memory B cells suggest an imbalance of the 155 GC reaction in MS.

157 We also conducted differential expression (DE) analysis for pseudobulked cell types. The 158 highest number of DE genes (DEG) in MS samples compared to controls were observed 159 in naïve CD4 T cells followed by plasmablasts, NK cells, and GC B cells (Fig. S1F, Data 160 file S5). In MS patients, plasmablasts upregulated several immunoglobulin (IG) heavy and 161 light chain genes compared to healthy controls. GC B cells upregulated CCDN2 (cyclin 162 D2, $P_{adi} = 0.024$, log2fc = 1.97) and downregulated LYN ($P_{adi} = 0.024$, log2fc = 0.93) in 163 the MS group as compared to controls. CCDN2 is upregulated during positive selection 164 in GCs (37), whereas loss of Lyn has been linked with a lupus-like autoimmune disease 165 with hyperactive B cells (38). Although statistically not significant, the expression of 166 canonical B cell marker CD19, known to regulate B cell proliferation in GC reaction (39), 167 was decreased in GC B cells of MS patients ($P_{adj} = 0.07$, log2fc = -1.12) in transcription level, and also in protein level ($P_{adj} = 5.9e-18$, log2fc = -0.47) together with CR1 ($P_{adj} =$ 168 169 6.7e-12, log2fc = -0.47) and CR2 (P_{adi} = 1.4e-17, log2fc = -0.55) (Fig. S1G). Interestingly, 170 the CR1 and CR2 expression on B cells is also decreased in systemic lupus 171 erythematosus and rheumatoid arthritis (40). Memory CD8+ T cells were upregulating an 172 IFNγ modulator *DKK3* (*Dickkopf-3*, P_{adj} = 0.0015, log2fc 2.12), *TIGIT* (P_{adj} = 0.038, log2fc 173 = 0.59), and cytotoxic granzymes A and K in MS patients compared to controls (GZMA, 174 P_{adi} = 0.038, log2fc = 0.44; GZMB, P_{adi} = 0.0028, log2fc = 0.50). DKK3 is upregulated in 175 EAE (41) and TIGIT has been shown to promote CD8+ T cell exhaustion (42). 176

177 Double-negative memory B cells are increased in MS patients

178 To further characterize the B cell compartment where we found most differences in 179 abundance, we sub-clustered B cells. We identified similar B cell subsets as presented in 180 Fig. 1C, in addition to a T cell cluster initially clustered with memory and naïve B cells due 181 to a similar expression profile (Fig. S2A, Data file S6). The proportion of naïve B cells was 182 increased in MS dcLNs after removing the remaining T cells (p = 0.035 and log2fc = 0.82, 183 Fig. S2B, Data file S7). Then we sub-clustered the memory and naïve B cells presented 184 in Fig. S2A and identified clusters of CD27 positive and IgD negative switched memory 185 (SM), CD27 and IgD positive unswitched memory (USM), and CD27 and IgD low double

186 negative (DN) B cells in addition to naïve B cells with the combination of both transcript 187 and protein level information (Fig. 2A-B, Fig. S2C, Data file S8). MS patients had elevated 188 proportions of the USM, SM, and naïve B cells, yet only the proportion of DN B cells was 189 significantly larger (% of B cells, p = 0.041 and log2fc = 1.82, Fig. 2C; % of all cells, p =190 0.048 and log2fc = 2.51, Fig. S2D, Data file S9). Of note, DN B cells expressed less 191 CXCR5 than SM and USM B cells at both RNA and protein levels (Fig. 2B, Fig. S2C), 192 indicating that DN B cells could have been derived extrafollicularly (43, 44). Despite being 193 limited by cell numbers from dcLNs, in a subset of samples with higher cell yields, we 194 also performed flow cytometry analysis of the B cell compartment (see Methods, Fig. 195 S2E). We adapted the gating strategy from (45) and observed that the proportion of GC 196 B cells (CD19+CD20+CD38++CD10+lgD-) was reduced in MS patients compared to 197 controls and the proportions of memory (CD19+CD20+CD27+) and naïve 198 (CD19+CD20+IgD+CD27-CD38-) B cells were increased, however, due to the small 199 sample size, these results did not reach statistical significance (Fig. S2F). Moreover, 200 when dissecting the memory B cell compartment, the proportions of SM 201 (CD19+CD20+CD27+lgD-lgM-CD38-) and DN (CD19+CD20+CD27-lgD-lgM-CD38-) B 202 cells were higher in MS patients, however again without statistically significant difference 203 to healthy controls (Fig S2F). The flow cytometry results align with our findings from the 204 scRNAseg/CITEseg data, corroborating our observations of a larger memory B cell 205 compartment together with fewer GC B cells in the dcLNs of MS patients.

206

207 Next, we sub-clustered the GC B cells to study the GC reaction more thoroughly. We 208 identified CD83 and BCL2A1 expressing light zone (LZ) B cells (46, 47), CXCR4, AICDA, 209 and MKI67 expressing dark zone (DZ1, DZ2) B cells (46, 47), and an unidentified GC B 210 cluster (GC.B) characterized with MS4A1/CD20 and MKI67 and negligible CD3 211 expression (Fig. 2D-F, Data file S10). Active proliferation is a defining characteristic of 212 GC B cells, and that is why no cell-cycle correction was performed and explains why the 213 sub-clustering of GC B cells also contained a small cluster of proliferative T cells (Fig. 214 2G). Supporting the imbalanced GC reaction, we noticed that within the B cell 215 compartment, the proportion of GC B cell subsets of all B cells showed a lower trend in 216 MS patients (Fig. S2G). Within GC B cells, the GC.B cluster was significantly increased

in MS dcLNs compared to healthy controls (p = 0.011 and log2fc = 2.42, Fig. 2G, Data file S11). As expected, pathway analysis of cluster-defining DEGs ($P_{adj} < 0.05$) with GO biological processes showed a significant over-representation of pathways related to B cell activation and differentiation among upregulated genes of LZ B cells and replication among those of DZ B cells. Interestingly, the GC.B cluster, which was increased in MS patients, showed an over-representation of ribosomal genes related to viral transcription and viral gene expression (Data file S1).

224

225 Cellular interactions between follicular T cells and GC B cells

226 Since MS patients had an increased proportion of naïve B cells, memory B cells, and 227 PBs, while GC B cell and GC Tfh proportions were decreased compared to healthy controls, we hypothesized that the interaction between T and B cell subsets is altered. 228 229 To study intercellular interactions, we used NicheNet (48), which links transcripts of 230 ligands in sender cells to their transcript targets in the receiver cell. Principally 231 developing GC B cells rely on signals from Tfh via CD40 – CD40L interaction to 232 undergo SHM and class-switching (49). Similarly, the most active CD40 – CD40LG 233 interactions for GC B cells were predicted between GC Tfh and Tfh-like cells (Fig. 3A). 234 Integrins prolong interactions between T and B cells (50), and interestingly CD40LG – 235 ITGB1 (integrin beta 1) interaction was observed only between GC Tfh and GC B cells 236 emphasizing their crosstalk in GCs. GC Tfh cells were the only CD4+ T cells which 237 interacted with GC B cells via CD28 – CD86 and CD28 – CD80, of which the latter is 238 reported to be crucial for T-B interactions in GC responses (51). Contrary to our 239 hypothesis, the above interactions between GC B cells and Tfh cells were similar for MS 240 patients and controls when compared using MultiNicheNet (52) (Fig. S3A). We 241 observed a slight increase in galactin-1 (LGALS1) – lectin receptor CD69 interaction 242 between GC B and Tfh cells in MS patients (Fig. S3A), of which galactin-1 is shown to 243 favour PB differentiation (53). We did not observe IL21 – IL21R interaction between GC 244 B cells and GC Tfh cells, however, this could have been affected by the small 245 proportions of both cell subsets. Instead, IL21 – IL21R interaction was increased 246 between GC Tfh and naïve B cells, suggesting that part of the naïve B cells could have

already been dedicated for the GC reaction (33) (Fig. 3A). In line with this, *CD40LG* – *CD40* interaction between GC Tfh/Tfh-like cells and naïve B cells was decreased in MS
patients compared to GC B cells (Fig. S3A). The naïve B cells dedicated to the GC
reaction could potentially receive less necessary proliferative signals from Tfh cells in
MS patients, which could lead to an altered GC response.

253 The precise mechanisms of how Tfr cells control the GC reaction and selection of Tfh 254 and GC B cell clones are largely unknown. Here, Tfr cells were predicted to interact with 255 GC B cells via CD28 – CD80/CD86 (Fig. 3A), which is needed for Tfr differentiation 256 (54). We did not observe CTLA4-mediated inhibition of CD80/CD86 costimulatory 257 signals between Tfr and GC B cells, which has been thought to play a key role in the 258 regulation of GC reaction (55). B cell proliferation, memory responses, and CXCR5 259 expression of GC B cells are downregulated via HLA-G – LILRB1 (also known as ILT2) 260 interaction between T and B cells (56). B2M (beta-2-microglobulin) constitutes the light 261 chain of HLA-G, and B2M – LILRB1 interaction was predicted only between Tfr and GC 262 B cells (Fig. 3A). Possibly B2M – LILRB1 interaction is one mechanism for Tfr cells to 263 regulate GC B cell development and thus, GC reaction. 264

GC B cells are less clonal in dcLNs of MS patients

266 We evaluated the BCR repertoire in dcLNs of MS patients and healthy controls. On 267 average, BCRs from 1400 cells per MS patient and 882 per healthy control sample were 268 obtained. We observed no difference in the diversity of the total BCR repertoire (Fig. 3B), 269 nor in the BCR diversity of naïve B cells, memory B cells, or plasmablasts between 270 patients and controls (Fig. S3B). However, the BCR diversity of GC B cells was 271 significantly higher in MS patients when compared to healthy controls (Fig. 3C). To 272 confirm this, we used the Lanz et al. (8) definition for BCR clonotypes (see Methods) 273 where we still observed significantly increased diversity only in the GC B cell compartment 274 of MS patients (Fig. S3C). In summary, while we could detect a lower proportion of GC B 275 cells in MS dcLNs (Fig. 1H), their standardized BCR diversity was higher than in healthy 276 controls.

278 TCR repertoire in dcLNs is similar between MS patients and controls

279 From T cells we obtained single-cell paired TCR $\alpha\beta$ data for an average of 6124 cells 280 per MS patient and 6702 for healthy control, corresponding to 5851 and 6384 average 281 unique TCR clonotypes, respectively (Fig. S3D). Comparison of TCR diversity in the 282 entire dcLN-paired-TCRαβ repertoire, with and without downsampling to the same read-283 depth, showed no statistical difference in TCR clonality between MS and healthy 284 controls (Fig. 3D). We also found no statistical difference in repertoire diversity within 285 specific T cell subpopulations between patients and controls (Fig. S3E). To determine 286 the possibility of more TCR sharing among MS patients, we also compared TCR amino 287 acid level overlap rates for every possible pair between patients and controls, however, 288 no evidence for increased TCR overlap in MS dcLNs was found (Fig. S3F).

289

290 Given the decreased GC B cell clonality and proportion in MS dcLNs, we examined 291 follicular T cells closer. Only a few TCRs of Tfh-like, GC Tfh, and Tfr cells were shared 292 with TCRs from other T cell subsets within each individual, with no difference between 293 MS patients and controls (Fig. S3G). Tfr cells shared TCR clones with both Treg (in 3/6 294 MS patients and 1/3 controls) and Tfh-like cells (in 1/6 MS patients and 1/3 controls), 295 indicating that Tfr cells had developed from both cell types. A trajectory analysis of the 296 scRNA-seg data from Tfh-like, GC Tfh, Tfr, and Treg cells using slingshot (57) showed 297 a single developmental trajectory encompassing from Tfh-like cells via GC Tfh and Tfr 298 to Treg cells, suggesting that Tfr cells had developed from both Tfh and Treg cells, in 299 line with recent findings (Fig. S3H) (58).

300

To compare the antigen-driven TCR repertoire in the patients' dcLNs to controls, we scanned the VDJdb database for possible specificity of all our TCR $\alpha\beta$ amino acid clonotypes using tcrdist3 (see Methods). Predicted T-cell-specificity was higher in MS patients towards epitopes of M.tuberculosis in Naïve CD4s (p-value=0.03, log2fc = 0.5), Influenza A (p-value = 0.003, log2fc = 3) and EBV (marginally with p-value = 0.08 & log2fc = 0.56) in GC Tfh cells (Fig. S3I), however, these were insignificant after we filtered for

HLA restriction of target TCRs (retaining HLA class 2 restricted hits for CD4+ T cells, and
 HLA class 1 restricted hits for CD8+ T cells).

309

Higher coverages of EBV, HHV-6B and HHV-7 in dcLNs and viral loads of EBV in the saliva of MS patients

All MS patients were seropositive for EBV viral capsid antigen (VCA) IgG (9/9), whereas only five of the six controls were EBV VCA IgG seropositive. Of the EBV VCA IgG seropositive individuals, MS patients had higher EBV VCA IgG titer than healthy controls (p = 0.019, Fig. S4A). None of the subjects were seropositive for EBV VCA IgM.

316

317 Next, by using hybrid-capture sequencing, we searched for common human DNA viruses 318 from fine needle aspirations of dcLNs (n_{MS} =4, n_{hc} =4, Fig. 1A). The prevalence of EBV 319 (75% vs 50%, human-herpesvirus-6B (HHV-6B, 50% vs 0%), and HHV-7 (100% vs 75%), 320 but also the total number of unique viral reads covering the reference sequences, which 321 correlates to the viral copy numbers (59), was higher in MS patients compared to controls 322 (Fig. 4A, Table 2). The coverages of HHV-7 were particularly higher in MS patients, from 323 whom we were able to reconstruct two near-complete viral genomes. Three out of four 324 MS patients were positive for parvovirus B19 (B19V) compared to 100% of controls. Equal 325 prevalence (50%) of Merkel cell polyomavirus was detected in both MS patients and 326 healthy controls. Importantly, MS patients and healthy controls clustered into separate 327 clusters based on the breadth coverage profiles of the above-tested viruses (Fig. 4A). We 328 aligned the scRNA-seq data to reference viral genomes available at ViruSITE (60) and 329 NCBI (61) databases (see Methods) including EBV genome to identify cells producing 330 viral transcripts (62). However, we did not find any cells producing transcripts of EBV, or 331 other herpesviruses.

332

Using multiplex qPCR HERQ-9 quantification we searched for EBV DNA from the saliva
as a sign of EBV reactivation. We found three out of nine HHVs in the saliva of MS patients
and controls: EBV, HHV-6B, and HHV-7. Herpes simplex virus-1 (HSV-1), HSV-2,
varicella-zoster virus, CMV, HHV-6A or Kaposi's sarcoma-associated herpesvirus were

not detected in any of the samples. EBV was found from saliva in all except one of the
MS patients in contrast to only one of the controls, and the viral loads in MS patients were
significantly higher (p = 0.011) (Fig. 4B). Surprisingly, the MS patient negative for EBV
DNA in dcLN had the highest EBV viral load in saliva. HHV-6B was found in most samples
and HHV-7 in all without significant differences in the viral loads for either of these viruses
between groups (Fig. S4B).

343

Patient with an active MS relapse exhibits EBV targeting memory CD8 cells, skewed follicular T cell ratios, and negligible GC B cells

346 Immunological processes during active MS relapse are poorly understood, partly 347 because treatment is usually started soon after hospital admission. We managed to 348 obtain dcLN FNA from one patient during hospitalisation for an active MS relapse before 349 immunomodulatory treatments were started. The patient (MS011) had no other known 350 diseases besides MS nor an immediate history of infections and exhibited weakness of 351 the right leg and diplopia with EDSS of 3.5 in the clinical evaluation during the relapse 352 (Table 1). The patient's plasma EBV VCA IgG concentration and copy numbers of 353 HHVs in saliva were comparable to MS patients (Table 2). 354 355 When comparing cell abundancies from dcLNs, we observed that the patient had the 356 highest proportions of PBs, Tfh-like, and memory CD8 T cells, and the lowest

proportions of naïve, intermediate, and effector CD4, GC Tfh, Tfr, and GC B cells
across all subjects (Fig. 1G, Fig. S5A). The abundance of memory and naïve B cells

359 were similar to those in other patients. The ratio of GC Tfh to Tfh-like cells was reduced,

360 while the total Tfh to Tfr ratio was significantly increased (Fig. 5A), both likely due to the

361 drastic increase of Tfh-like cells (Fig. S5A). Moreover, the patient had the lowest

proportion of DZ and LZ B cells of all B cells. Within the GC B cell compartment the

363 cluster of GC.B cells, characterized by upregulation of transcripts involved in pathways

of viral transcription and viral gene expression, was significantly increased (Fig. 2G,

365 S2D, S5B).

367 We also redid analysis on cellar abundancies between patients and controls after 368 excluding the patient with acute exacerbation to evaluate how much of the results were 369 affected by the acute case. After excluding the acute relapse patient, non-treated MS 370 patients still had significantly increased memory and naïve B, and effector CD4 T cells, 371 decreased GC B, naïve CD4, and CD8, and intermediate CD4 T cells, and marginally 372 decreased GC Tfh cells (Fig. 5B). To conclude, the alterations of lymphocytes 373 characterized with larger memory B cell compartment and smaller proportion of GC B 374 cells in dcLNs seem more pronounced in early MS during a relapse.

375

376 The patient had the highest number of all BCRs and PB BCRs (Fig. 5C), whereas the 377 lowest of GC B cell BCRs (5 GC B cell BCRs of 1758 detected BCRs, detected BCRs in 378 all samples ranged from 599 to 1758). On the TCR side, while the relative frequency of 379 expanded T-cell clonotypes was not statistically different between the patient groups, 380 the largest percent of cells from expanded TCR clonotypes was seen in the patient with 381 relapse (1.16% of all T cell clonotypes were expanded, the median in MS patients is 382 0.40% and in controls 0.15%; paired TCR clonotypes with frequencies of over 0.001 of 383 all clonotypes within each sample were considered expanded), of which the most (84%) 384 were memory CD8 T cells (Fig. 5D). Notably, the majority of the clonally expanded T 385 cells from the patient were predicted to be EBV specific, whereas no EBV specific TCRs 386 were seen in T cells of other subjects (Fig. 5E). We validated and refined the TCR 387 predictions with an orthogonal method TCRGP, which has outperformed the original 388 tcrdist algorithm (63). With TCRGP, we confirmed the enrichment of clonally expanded 389 CD8+ TCR specific to EBV antigen EBNA3B in the patient with an active relapse (Fig. 390 S5C, P_{adj} = 0.0002, odds ratio (OR) = 18.80, Benjamini-Hochberg corrected one-sided 391 Fisher's exact test).

392 **DISCUSSION**

393 Therapeutic advances during the last decades have highlighted the role of B cells and 394 T-B crosstalk in MS pathogenesis. Examining B cell subsets at the site where B cell-395 mediated immunity evolves is essential for gaining a deeper understanding of the origin 396 of MS and for elucidating why systemic B cell-depletion effectively treats the disease. 397 Here, to the best of our knowledge, we have provided the first-ever characterization of 398 the single-cell immune landscape in the dcLNs of newly diagnosed MS patients by 399 coupling scRNA-seq with CITE-seq. The B cell compartment of dcLNs is altered in MS 400 patients with an increase in memory B cells and decreased GC B cells with reduced 401 clonality suggesting a disturbance of GC reactions. Hybrid-capture sequencing of 402 eukaryotic DNA virome detected EBV, HHV-6B and HHV-7 DNA more readily in the 403 patients' dcLNs than the controls. Moreover, using multiplex qPCR from the saliva 404 against common herpesviruses, EBV DNA was witnessed primarily in the patients and 405 not the controls. In addition, the MS patient sampled during an acute relapse presented 406 with starker findings in the same B cell subsets together with clonally expanded memory 407 CD8+ T cells whose TCRs were likely targeting EBV.

408

409 Expansion of memory B cells and plasma cells in the CSF of MS patients is well 410 demonstrated (8, 16, 64). Simultaneously, Tfh cells are more prevalent both in CSF of 411 MS patients and in MS animal models, where Tfh cells promote B cell accumulation and 412 disease progression (64). Therapeutic effect of systemic B cell depletion is mirrored in 413 CSF by a decrease in memory B cells, which further underlines the role of B cell 414 dysregulation in MS. Based on studies with twins (65) or with paired CSF and blood 415 samples (64, 66) the B cell expansion is restricted to the CNS, whereas peripheral 416 blood reflects the B cell compartment inadequately. Even though the expanded memory 417 B cells are shown to derive from the dcLNs (16), the role of dcLNs in MS has been 418 largely unstudied. To enlighten this, we investigated the dcLNs in MS patients and 419 controls and discovered that the proportion of memory B cells and to a smaller degree 420 PBs was augmented in dcLNs of MS patients. This suggests that the reported 421 expansion of intrathecal B cells, plasma cells (64) and circulatory memory B cells in 422 early MS (67) derive from alterations of B cell maturation in the dcLNs. In addition, MS

423 patients had fewer and less clonal GC B cells further suggesting dysregulation in GC 424 reaction. Also, the Tfh cells likely representing GC-resident Tfh cells (34) interacting 425 with GC B cells due to expression of BCL6 (28), ICOS (29), TOX2 (30), PDCD1 (31), 426 SH2D1A (SAP) (32) were decreased in MS patients. Tentatively, GC B cells could 427 receive less survival signals in the light zone from GC-resident Tfh cells leading to 428 favoring the B cell differentiation toward memory B cell fate over PB fate (49, 68) and to 429 GC contraction (69) in dcLNs of MS patients. This would subsequently explain the decrease of GC B cells in MS patients. Interestingly, autoimmunity-linked DN (45) but 430 431 also switched-memory B cells were increased in MS patients. Both of them could 432 develop in extrafollicular responses of the lymph node, not only in GCs (43). On the 433 other hand, Tfh cell-proportions were skewed especially in the patient with a relapse, in 434 which Tfh-like cells, that probably remain outside the GC (GC-nonresident Tfh), were 435 expanded. Chronic viral infections seem to favour Tfh differentiation, yet result in 436 dysregulated Tfh – GC B cell interactions (79). Hence, local activation of latent EBV 437 could be a driver for the GC-nonresident Tfh expansion during the disease relapses 438 leading to a larger memory B cell compartment in MS patients as observed here. 439 Further studies on larger datasets with paired CSF samples are warranted to 440 demonstrate whether altered GC reaction in dcLNs is the origin of clonally expanded 441 intrathecal B cells in MS, potentially opening the door to new therapeutic strategies. 442

443 Epidemiological evidence for EBV infection as a prerequisite for MS onset is strong. 444 However, the exact pathogenic mechanisms leading to MS after this ubiquitous viral 445 infection are still unresolved. Molecular mimicry between CNS structures and EBV has 446 been widely acknowledged (8), but why such reactions lead to CNS autoimmunity in 447 only a minority of humans infected with EBV remains still unresolved. Findings of EBV 448 from postmortem samples have been contradicting (70-72), thus an uncontrolled viral 449 activation or replication as the cause of MS is still debatable. Interestingly, spontaneous 450 proliferation of CD4+ T cells initiated by memory B cells has been reported in MS 451 patients with HLA-DR15 haplotype (73) and is stimulated by EBV peptides (74). 452 Considering the observed expansion of memory B cells in MS dcLNs, EBV-infected B 453 cells could be the source of uncontrolled proliferation of CD4+ T cells.

455 Contrary to previous results by Gieß et al (75), we observed EBV DNA in the saliva of 456 adult early MS patients, possibly due to a more sensitive method. Similarly, oral 457 shedding of EBV as a possible sign of EBV lytic cycle reactivation has been reported in 458 pediatric MS patients (76). We detected EBV DNA in higher prevalence in MS patients 459 dcLNs than in controls, however, we could not find cells producing EBV nor other 460 aforementioned viruses by aligning scRNA-seq reads to viral genomes. Yet, it should be 461 noted that the copies of the viruses detected by hybrid-capture sequencing were likely 462 to be few, and the low efficiency of scRNA-seg library preparation (77) limits the 463 likelihood of detecting cells with viral transcripts from the scRNA-seg data. Our findings 464 of EBV activation lead us to speculate whether, in early MS, relapses could rise from 465 local activation of latent EBV in dcLNs, which would not be detected systematically with 466 serological assays (78). Recently, EBV-specific memory CD8+ T cells were observed in 467 CSF of both healthy controls and MS patients, however, patients' had also central 468 memory CD8+ T cells associated with broader EBV-specific repertoires (80). In our 469 study, the patient with an ongoing relapse had expanded EBV targeting memory CD8+ 470 T cells, and it is possible that they expand and migrate to CNS during a relapse, since 471 this was not observed in patients without active relapses.

472

473 The understanding of GC reaction is largely based on experiments with mice, and 474 studies with human tissues, especially in autoimmunity are few since patient recruitment 475 and sample collection are challenging. Our dcLN data set from recently diagnosed MS 476 patients without immunosuppressive medication is unique, however, it is restricted with 477 the small sample size. Also, our scRNAseq experiments were limited to 10,000 cells per 478 sample, which impeded the T and B cell clonotype analysis. The majority of the VDJdb 479 database is based on CD8+ T cells, which could explain why we could not detect CD4+ 480 T cell subsets targeting several viruses, such as EBV. Despite the limited cell number 481 per sample, we studied paired TCR $\alpha\beta$ data from an average of 6124 T cells per MS 482 patient and 6702 per healthy control, which increases the specificity of our clonotype 483 results. Yet, we did not find any differences in repertoire diversity within specific T-cell 484 subpopulations when comparing MS patients to healthy controls, which suggests that

- 485 clonal expansion of specific T cell clones unlikely dominates in dcLNs outside the MS
- 486 relapses. The only EBV-targeting T cells were clonally expanded memory CD8+ T cells
- 487 found only in the MS patient with a relapse. Using TCRGP, we confirmed that the
- 488 memory CD8+ TCRs in the patient with relapse were specific to latency-associated EBV
- 489 antigen EBNA3B (7) and increased 18.8 times compared to healthy controls.
- 490
- 491 Our results encourage the use of FNA and scRNAseq to study lymphoid tissues,
- 492 including ectopic GCs in autoimmune infiltrates, in various diseases to better
- 493 understand autoimmune mechanisms and development of memory B cells and
- 494 plasmablasts. By investigating the single-cell immune microenvironment of dcLNs at the
- 495 diagnosis of MS, we observe increased memory B cell compartment along with
- 496 decreased GC B cells in comparison to healthy controls, suggesting malfunction of the
- 497 GC reaction in the patients. Paralleled with findings related to EBV and the known
- influence of EBV on GC dynamics (*81*), our results support B cell dysregulation as a key
 mechanism in MS pathogenesis.
- 500

501 MATERIALS AND METHODS

502 Study design

503 We studied the cellular compartment of dcLNs in MS patients and healthy controls using 504 ultrasound-guided FNAs. Viable single cells were isolated from the FNAs and 505 subsequently processed for 5' single-cell RNA sequencing and hybrid-capture 506 sequencing of DNA viruses (22). Also, blood and saliva were collected from the 507 participants for additional viral assays.

508

509 This study was approved by the Helsinki University Hospital ethical committee (decision 510 number 5774/2020; research permit number 2363/2020). All subjects participated 511 voluntarily and gave written informed consent according to the principles of the 512 Declaration of Helsinki. Nine newly diagnosed MS patients and 7 age and sex-matched 513 healthy controls were selected for this study between April 2021 and March 2022. MS 514 diagnosis was confirmed by an experienced neurologist at the Helsinki University 515 Hospital using the 2017 McDonald diagnostic criteria (82, 83). The full diagnostic 516 workup included evaluation by a neuroimmunologist, CSF analysis, and a head MRI. All 517 MS patients had oligoclonal bands in CSF at the time of diagnosis. We only chose MS 518 patients without any immunomodulatory medications. In addition, an absence of 519 intravenous glucocorticoid infusion within 3 months before sample collection was a part 520 of the inclusion criteria. Further patient characteristics are shown in Data file S1. 521

522 Sampling of blood and saliva

Blood and saliva were taken 1 to 3 hours before the FNA sample. Blood samples were collected into Li-heparin Vacutainer tubes (BD Biosciences), and plasma was separated by centrifugation and archived at -80 C° until enzyme-linked immunosorbent assay (ELISA). Subjects had a minimum of a 30-minute break from any liquids or solid foods before saliva samples were obtained. The samples were collected at noon to normalize the diurnal variation of protein secretion and stored at -20 C°. EBV serology status was

- 529 evaluated using Anti-EBV-CA ELISA IgG and IgM kits (Euroimmun, CAT#: El 2791-
- 530 9601 G, El 2791-9601 M) according to the manufacturer's instructions.

531 Fine needle aspirations

532 Ultrasound-guided FNAs of dcLNs and subsequent processing for single-cell 533 sequencing were performed as described previously by Turner et al (84). Briefly, 534 radiologists (G.K, R.L) first measured dcLNs (Table 1), after which they performed 535 FNAs under visualization with a 25-gauge needle. For each sample, 2 aspirations were 536 taken and collected into 3ml of 10% FBS in RPMI 1640 followed by three 0.5 ml rinses. 537 After one wash with 2% FBS and 0.5mM EDTA in PBS, red blood cells were eliminated 538 using 1ml of ACK lysis (Lonza) followed by another wash using PBS supplemented with 539 2% FBS and 0.5mM EDTA. Single-cell RNA sequencing was performed in 540 concentrations of 1x10⁷ cells per ml in calcium- and magnesium-free PBS with 0.04% 541 BSA solely or in parallel with the cellular indexing of transcriptomes and epitopes by 542 sequencing (CITE-seq). CITE-seq staining was performed for a minimum of 500,000 543 cells using TotalSeq[™]-C Human Universal Cocktail (BioLegend, cat 399905) according 544 to the manual. For the samples in which solely scRNAseq was performed, 10,000 cells 545 were targeted for sequencing. For part of the samples (Data file S1), a flow cytometry 546 assay was also performed to characterize B cell subsets (described further). The 547 remaining cells were frozen in RNA Later (Thermo Fisher) according to the 548 manufacturer's instructions at -80 C°.

549

550 Single-cell sequencing

scRNAseq was performed for 7/9 MS and 5/7 healthy control dcLN FNA samples of
 which CITE-seq was performed for 5 MS and all healthy control samples. FIMM Single Cell Analytics core center at the University of Helsinki performed 5'RNAseq run and
 library preparation for scRNAseq, TCRαβ, and BCR libraries using the Chromium Single

- library preparation for scRNAseq, TCR $\alpha\beta$, and BCR libraries using the Chromium Single
- 555 Cell 5' (v2 Chemistry Dual Index) with Feature Barcoding technology for Cell Surface
- 556 Protein and Immune Receptor Mapping (CITE-seq) as instructed by the manufacturer
- 557 (10X Genomics).

The sequencing was started immediately after FNA sample preparation and libraries
were sequenced on Illumina NovaSeq 6000 system (read lengths 26bp (Read 1), 10bp
(i7 Index), 10bp (i5 Index), and 90bp (Read 2). The raw scRNAseq data were
processed using Cell Ranger (v 2.2.0) against the human genome GRCh38. TCRαβ
and BCR data were processed with Cell Ranger vdj pipeline to generate single cell
V(D)J sequences and paired clonotype calling according to the manufacturer's
instructions.

566

567 Single-cell RNA, CITE-seq, and scTCR & BCR data analysis

568 Analysis of scRNAseq data was performed using Seurat (v4.1.1) in R (23). Initial QC was 569 performed separately for each sample in which cells in the top 2 percentile for 570 mitochondrial gene expression and in the top 1 percentile for the number of genes 571 detected were removed. Also, one MS sample and three healthy control samples with an 572 abnormally low number of cells due to technical issues in 10x runs were removed. The 573 remaining samples were combined for cluster analysis with the merge function in Seurat. 574 Uniform manifold approximation and projection (UMAP) was then performed in Seurat 575 using the top 50 principal components of the merged data. Graph-based clustering and 576 cluster labelling were performed with a resolution of 1 of the FindClusters function. The 577 resulting clusters were defined by cell types and were well mixed from all possible batches 578 (library and sequencing batches, Fig. S1A-D). In addition, no sample or patient group-579 specific misalignment of cell clusters was observed (Fig. 1B, Fig. S1E), thus no batch 580 correction of the dataset was needed. Cell-level cell-type annotation was mainly 581 performed with the reference-based SingleR method (v1.10.0) (25) using the Monaco 582 immune data as a reference (26). The most frequent cell-level annotation was assigned 583 to each cluster, and cell clusters with the same annotation were readily combined. We 584 then confirmed and refined the cluster-level annotations manually using cluster markers 585 detected from the scRNA-seg and CITE-seg data (Fig. 1D-E) and annotated additional 586 cell types of interest (such as GC B cells, Tfh-like, GC Tfh, Tfr) that were missing in the 587 reference data for SingleR. We also performed sub-clustering of B cell subsets, for which

cluster annotations were performed manually based on cluster markers detected from the
 scRNA-seq and CITE-seq data (Fig. 2, Data file S6,8,10).

590

591 We then used the cell clusters as defined by the annotation above for further analyses. 592 To identify differentially abundant cell types in MS, cell type composition was evaluated 593 between MS and control samples by comparing the proportion of the cell types in the two 594 conditions. Differential gene expression was identified for each cell type using the 595 pseudobulk approach, which has been reported to outperform other single-cell DE 596 methods (85), by sum aggregating the RNA counts of genes per cell type per sample, 597 and comparing the pseudobulk gene expression within each cell type between MS and 598 controls using DESeq2 (v1.36.0) (86). Biological pathway analysis was then performed 599 for each cell type using the pathway-express method (R package ROntoTools v2.24.0) 600 (87, 88).

601

602 Basic evaluation and comparison of immune single-cell level TCR and BCR repertoire 603 clonality/diversity and clonal overlap were done with scRepertoire (v1.6.0) (89) and in-604 house custom R script. We scanned the VDJdb database (release 2022-03-30) (90) of 605 known TCR-epitope targets for possible specificity of our TCRs using tcrdist3 (v0.2.2) 606 (91), with a tordist3 distance of less or equal to 12 per alpha and beta chain (translating 607 to one amino acid mismatch per chain) used to assign possible targets for our TCRs. 608 This was done for paired TCRab, and the specificity profiles were compared between MS 609 patients and controls. For validation, TCRGP (1.0.0) (63) models were made for the 28 610 HLA class I-restricted epitopes from endemic viruses (CMV, EBV, Influenza A). For the 611 predictions, only CD8+ T cells were used and a threshold corresponding to a false positive 612 rate (FPR) of 5% was determined for each epitope separately from the receiver operating 613 characteristic (ROC) curves obtained from the cross-validation experiments, as described 614 previously For BCRs, clonality definition in scRepertoire was used, i.e., BCRs using the 615 same V gene for both heavy and light chains (HC and LC), and that have >85% nucleotide 616 similarity in the HC and LC CDR3s (with normalized Levenshtein distance) were grouped 617 into one clonotype. For comparison with our results, we also used the clonotype definition 618 by Lanz et al. 2022 (8), i.e., sharing the same HC and LC V and J genes, and exhibiting

619 >70% amino acid identity within the HC and LC CDR3s (with normalized Levenshtein620 distance).

621

Human leukocyte antigen (HLA) genotypes were predicted from the scRNA-seq data with arcasHLA (92), which has recently been shown to have better accuracy than other similar tools (93). The HLA-DR15 allele with the strongest risk for MS, HLA-DRB1*15:01(74), was present in all (3/3) of the healthy controls and half (3/6) of the MS patients (Data file S1), suggesting that the observed TCR/BCR repertoire changes in our MS patients are more likely caused by other reasons than due to HLA-DR15 allele.

628 Intercellular communication analysis

629 We used the NicheNet package (v. 2.0.1) (48) to study differences in intercellular 630 communications between observed cell types. In each combination of sender and 631 receiver cell type, genes that were expressed in at least 10% of the sender/receiver cell 632 type population and present in the pre-built NicheNet prior ligand-receptor interaction 633 model were chosen as potential receptor and ligand genes. In addition to ligand activity 634 analysis, the ligands were prioritized based on condition-specificities of the ligands and 635 receptors across all cell types to highlight any ligands and receptors expressed 636 differentially between MS patients and controls. We visualized the top ligand-receptor 637 pairs for each sender-receiver cell type combination using the mushroom plot function 638 offered by NicheNet. In addition, the MultiNicheNet package (v. 1.0.3) (52) was used to 639 observe differences between controls and MS patients. For the analysis, we followed the 640 main steps in the MultiNicheNet vignette.

641 Detection of viruses from scRNAseq data

To detect any EBV-producing cells, we used the Vulture pipeline (*62*), which utilizes viral and prokaryote genome files from the ViruSITE (*60*) and NCBI (*61*) databases along with alignment tools to map 10x scRNA-seq reads to microbial genomes. Vulture was used together with the CellRanger alignment tool to map the raw scRNA-seq data to the microbial genomes. After performing QC on the mapped reads, we normalized the 647 obtained counts across each sample. This enabled comparing the counts of microbial648 features across samples.

649 Hybrid-capture sequencing of DNA viruses from dcLN FNAs

650 The DNA was extracted using the QIAamp DNA Mini Kit (Qiagen), following the 651 manufacturer's protocol for tissue extraction. The extracts were eluted in 60 ul of AE 652 buffer and the DNA was mechanically fragmented with a Covaris E220 with a target 653 length of 200 nt. Subsequently, the libraries were prepared with the KAPA HyperPlus kit 654 (Roche) using unique Dual Index Adapters (Roche). Targeted enrichment of the viral 655 DNAs was performed using a custom panel of biotinylated RNA probes (Arbor 656 Biosciences) as described by Toppinen et al (22). Each sample was individually 657 enriched via two rounds of hybridization, following the manufacturer's recommendations 658 for low-input DNA (MyBaits v5 kit; Arbor Biosciences). The probes were 100 bp in 659 length and designed with 2X tiling. Kapa Universal Blockers (Roche) were used to block 660 unspecific binding to the adapters during hybridization. 661

During library preparation and viral enrichment, the libraries were amplified 3x13-25
cycles. The clean-up steps were performed with 1x KAPA HyperPure Beads (Roche).
The enriched libraries were quantified with the KAPA Library Quantification Kit (Roche)
using Stratagene 3005P qPCR System (Agilent) and pooled for sequencing on
NovaSeq 6000 (one lane, S4, PE151 kit; Illumina).

667

668 Data analysis of hybrid-capture sequencing

- 669 The data analysis was done with TRACESPipeLite, a streamlined version of
- 670 TRACESPipe (94). The paired-end reads were trimmed and collapsed with
- 671 AdapterRemoval, cutting ambiguous bases at the 5'/3' termini with quality scores below
- 672 or equal to two. Reads shorter than 20 bases were discarded. FALCON-meta was used
- to find the highest similar reference from the NCBI viral database (95). The reads were
- aligned with BWA (96) using a seed length of 1000 and a maximum diff of 0.01. Read
- 675 duplicates were removed with SAMtools (97) and the consensus sequences were

- 676 reconstructed with BCFtools (98). The coverage profiles were created with BEDtools
- 677 (99). When in low breadth coverage (< 10%), the individual reads were manually
- 678 inspected and confirmed by BLAST. The pipeline is freely available, under the MIT
- 679 license, at <u>https://github.com/viromelab/TRACESPipeLite</u>, along with the code (included
- 680 in the TRACESPipeLite repository).

681 Quantitative multiplex PCR (qPCR) of saliva

- 682 DNA extraction was optimized by adapting the protocol from Qiagen QIAamp DNA
- Blood Mini Kit and Qiagen DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) to get
- the highest yield of DNA. Initially, 8 ml of phosphate-buffered saline (PBS) (Lonza,
- Basel, Switzerland) was added to 2 ml of each saliva sample. The samples were then
- $_{686}$ centrifuged at 1800 g for 10 minutes. The pellet was resuspended in 180 μl ATL buffer
- by pipetting up and down. The sample was pipetted into a new tube with 40 μl
- 688 proteinase K, vortexed, and incubated at 56°C with shaking for 1 h. After this, 200 μl AL
- buffer was added followed by vortex and incubation at 70°C for 10s min. From here, the
- 690 protocol continued following the Qiagen QIAamp DNA Blood Mini Kit Spin Protocol. In
- 691 the last step, DNA was eluted into 60 μl AE buffer with an incubation time of 5 min. The
- 692 samples were stored at -20°C until further processing.
- 693
- 694 Multiplex qPCR method HERQ-9 was used to detect and quantify nine HHVs
- 695 simultaneously from the saliva samples as described earlier by Pyöriä et al (100).
- Briefly, HERQ-9 is designed in three triplex-qPCR reactions, the first one amplifying
- 697 herpes simplex viruses 1 and 2 (HSV-1 and 2) and varicella-zoster virus (VZV), the
- 698 second one amplifying EBV, human cytomegalovirus (HCMV), and Kaposi's sarcoma-
- associated herpesvirus (KSHV), and the third one amplifying HHV-6A, -6B, and -7. The
- viral loads were normalized per 10⁶ cells, determined with the human single-copy gene
- 701 RNase P qPCR (101).

702 Flow cytometry

For cell surface staining, cells were suspended in an antibody cocktail containing
 LIVE/DEAD® Fixable Green Dead Cell Stain (ThermoFisher), which was prepared

- vising Brilliant Stain Buffer (BD Biosciences). The cell suspension was then incubated at
- ⁷⁰⁶ +4°C for 30 minutes and subsequently washed twice with FACS staining buffer (PBS,
- pH 7.4, 10% FBS, and 2 mM EDTA). Flow cytometry data were acquired with LSR
- 708 Fortessa (BD Biosciences) and analyzed with FlowJo (BD Biosciences, LLC). Detailed
- information about the antibodies used in this study can be found in Data file S13.

710 Statistics

- 711 Either the t-test or evaluation of the standardized Pearson residuals using the Chi-
- 712 Square test was used to compare two different categories. In the chi-squared test, all
- cells were pooled by subject group and the overall cell type distribution frequency of the
- 514 standardized Pearson residuals was compared between MS patients and healthy
- controls. Euclidean dissimilarity distances and either Ward's or complete agglomerative
- clustering were used in the correlation plots. In differentially expressing markers (both
- scRNA-seq and CITE-seq) analysis, the non-parametric Wilcoxon rank sum test was
- used and adjustments for multiple testing were performed with Bonferroni correction.
- 719 Nominal and adjusted p-values (P_{adj}) of less than 0.05 were considered significant. In
- the box plots, the vertical line corresponds to the median, the box corresponds to the
- interquartile range (IQR), and the whiskers are 1.5 × the IQR. All calculations were done
- 722 with R (4.2.1, 4.3.1) or Python (3.7.4).

723 Supplementary Materials

- 724 Supplementary Material on cluster phenotyping
- 725 Supplementary Figures 1-5
- 726 Description of supplementary datafiles
- 727

728 **References**

- C. Walton, R. King, L. Rechtman, W. Kaye, E. Leray, R. A. Marrie, N. Robertson, N. La Rocca, B. Uitdehaag, I. van der Mei, M. Wallin, A. Helme, C. Angood Napier, N. Rijke, P. Baneke, Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. *Mult. Scler.* 26, 1816–1821 (2020).
- J. M. Fletcher, S. J. Lalor, C. M. Sweeney, N. Tubridy, K. H. G. Mills, T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. *Clin. Exp. Immunol.* **162**, 1–11 (2010).
- O. L. Hatton, A. Harris-Arnold, S. Schaffert, S. M. Krams, O. M. Martinez, The
 interplay between Epstein-Barr virus and B lymphocytes: implications for infection,
 immunity, and disease. *Immunol. Res.* 58, 268–276 (2014).
- 739 S. Abrahamyan, B. Eberspächer, M.-M. Hoshi, L. Aly, F. Luessi, S. Groppa, L. 4. 740 Klotz, S. G. Meuth, C. Schroeder, T. Grüter, B. Tackenberg, F. Paul, F. Then-741 Bergh, T. Kümpfel, F. Weber, M. Stangel, A. Bayas, B. Wildemann, C. Heesen, U. 742 Zettl, C. Warnke, G. Antony, N. Hessler, H. Wiendl, S. Bittner, B. Hemmer, R. Gold, 743 A. Salmen, K. Ruprecht, German Competence Network Multiple Sclerosis 744 (KKNMS), Other members of the KKNMS that acted as collaborators in this study, 745 Complete Epstein-Barr virus seropositivity in a large cohort of patients with early 746 multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 91, 681–686 (2020).
- 747 5. R. Dobson, J. Kuhle, J. Middeldorp, G. Giovannoni, Epstein-Barr-negative MS: a
 748 true phenomenon? *Neurol Neuroimmunol Neuroinflamm*. 4, e318 (2017).
- K. Bjornevik, M. Cortese, B. C. Healy, J. Kuhle, M. J. Mina, Y. Leng, S. J. Elledge,
 D. W. Niebuhr, A. I. Scher, K. L. Munger, A. Ascherio, Longitudinal analysis reveals
 high prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science*(2022), doi:10.1126/science.abj8222.
- 753 7. S. S. Soldan, P. M. Lieberman, Epstein-Barr virus and multiple sclerosis. *Nat. Rev.* 754 *Microbiol.* 21, 51–64 (2023).
- T. V. Lanz, R. C. Brewer, P. P. Ho, J.-S. Moon, K. M. Jude, D. Fernandez, R. A.
 Fernandes, A. M. Gomez, G.-S. Nadj, C. M. Bartley, R. D. Schubert, I. A. Hawes,
 S. E. Vazquez, M. Iyer, J. B. Zuchero, B. Teegen, J. E. Dunn, C. B. Lock, L. B.
 Kipp, V. C. Cotham, B. M. Ueberheide, B. T. Aftab, M. S. Anderson, J. L. DeRisi, M.
 R. Wilson, R. J. M. Bashford-Rogers, M. Platten, K. C. Garcia, L. Steinman, W. H.
 Robinson, Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and
 GlialCAM. *Nature* (2022), doi:10.1038/s41586-022-04432-7.
- D. F. Angelini, B. Serafini, E. Piras, M. Severa, E. M. Coccia, B. Rosicarelli, S.
 Ruggieri, C. Gasperini, F. Buttari, D. Centonze, R. Mechelli, M. Salvetti, G.
 Borsellino, F. Aloisi, L. Battistini, Increased CD8+ T cell response to Epstein-Barr
 virus lytic antigens in the active phase of multiple sclerosis. *PLoS Pathog.* 9,
 e1003220 (2013).

- G. P. van Nierop, J. Mautner, J. G. Mitterreiter, R. Q. Hintzen, G. M. G. M. Verjans,
 Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr
 virus proteins. *Mult. Scler.* 22, 279–291 (2016).
- M. Abdel-Aziz, H. El-Hoshy, M. Rashed, M. Qotb, S. Awad, N. Naguib, Epstein-Barr
 virus infection as a cause of cervical lymphadenopathy in children. *Int. J. Pediatr. Otorhinolaryngol.* **75**, 564–567 (2011).
- 12. B. A. Plog, M. Nedergaard, The Glymphatic System in Central Nervous System
 Health and Disease: Past, Present, and Future. *Annu. Rev. Pathol.* 13, 379–394
 (2018).
- M. S. Albayram, G. Smith, F. Tufan, I. S. Tuna, M. Bostancıklıoğlu, M. Zile, O.
 Albayram, Non-invasive MR imaging of human brain lymphatic networks with
 connections to cervical lymph nodes. *Nat. Commun.* **13**, 203 (2022).
- M. van Zwam, R. Huizinga, M.-J. Melief, A. F. Wierenga-Wolf, M. van Meurs, J. S.
 Voerman, K. P. H. Biber, H. W. G. M. Boddeke, U. E. Höpken, C. Meisel, A. Meisel,
 I. Bechmann, R. Q. Hintzen, B. A. 't Hart, S. Amor, J. D. Laman, L. A. Boven, Brain
 antigens in functionally distinct antigen-presenting cell populations in cervical lymph
 nodes in MS and EAE. *J. Mol. Med.* **. 87**, 273–286 (2009).
- F. Di Giuliano, M. Albanese, E. Picchi, F. Mori, F. Buttari, G. A. Marfia, F. Garaci,
 N. B. Mercuri, R. Floris, D. Centonze, S. Marziali, Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study. *Radiol. Med.* 123, 202–208
 (2018).
- J. N. H. Stern, G. Yaari, J. A. Vander Heiden, G. Church, W. F. Donahue, R. Q.
 Hintzen, A. J. Huttner, J. D. Laman, R. M. Nagra, A. Nylander, D. Pitt, S. Ramanan,
 B. A. Siddiqui, F. Vigneault, S. H. Kleinstein, D. A. Hafler, K. C. O'Connor, B cells
 populating the multiple sclerosis brain mature in the draining cervical lymph nodes. *Sci. Transl. Med.* 6, 248ra107-248ra107 (2014).
- 17. C. Gago da Graça, L. G. M. van Baarsen, R. E. Mebius, Tertiary Lymphoid
 Structures: Diversity in Their Development, Composition, and Role. *J. Immunol.* 206, 273–281 (2021).
- 796 18. O. W. Howell, C. A. Reeves, R. Nicholas, D. Carassiti, B. Radotra, S. M.
 797 Gentleman, B. Serafini, F. Aloisi, F. Roncaroli, R. Magliozzi, R. Reynolds,
 798 Meningeal inflammation is widespread and linked to cortical pathology in multiple
 799 sclerosis. *Brain.* 134, 2755–2771 (2011).
- M. Stebegg, S. D. Kumar, A. Silva-Cayetano, V. R. Fonseca, M. A. Linterman, L.
 Graca, Regulation of the Germinal Center Response. *Front. Immunol.* 9, 2469
 (2018).
- 803 20. M. Puthenparampil, A. Zito, G. Pantano, L. Federle, E. Stropparo, S. Miante, G. De
 804 Silvestro, M. Plebani, P. Gallo, Peripheral imbalanced TFH/TFR ratio correlates

- with intrathecal IgG synthesis in multiple sclerosis at clinical onset. *Mult. Scler.*2018/06/09, 1352458518779951 (2018).
- 21. C. Havenar-Daughton, I. G. Newton, S. Y. Zare, S. M. Reiss, B. Schwan, M. J. Suh,
 F. Hasteh, G. Levi, S. Crotty, Normal human lymph node T follicular helper cells
 and germinal center B cells accessed via fine needle aspirations. *J. Immunol. Methods.* 479, 112746 (2020).
- 811 22. M. Toppinen, D. Pratas, E. Väisänen, M. Söderlund-Venermo, K. Hedman, M. F.
 812 Perdomo, A. Sajantila, The landscape of persistent human DNA viruses in femoral
 813 bone. *Forensic Sci. Int. Genet.* 48, 102353 (2020).
- Y. Hao, S. Hao, E. Andersen-Nissen, W. M. Mauck 3rd, S. Zheng, A. Butler, M. J.
 Lee, A. J. Wilk, C. Darby, M. Zager, P. Hoffman, M. Stoeckius, E. Papalexi, E. P.
 Mimitou, J. Jain, A. Srivastava, T. Stuart, L. M. Fleming, B. Yeung, A. J. Rogers, J.
 M. McElrath, C. A. Blish, R. Gottardo, P. Smibert, R. Satija, Integrated analysis of
 multimodal single-cell data. *Cell.* 184, 3573-3587.e29 (2021).
- 819 24. M. Büttner, Z. Miao, F. A. Wolf, S. A. Teichmann, F. J. Theis, A test metric for
 820 assessing single-cell RNA-seq batch correction. *Nat. Methods.* 16, 43–49 (2019).
- 25. D. Aran, A. P. Looney, L. Liu, E. Wu, V. Fong, A. Hsu, S. Chak, R. P. Naikawadi, P. J. Wolters, A. R. Abate, A. J. Butte, M. Bhattacharya, Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat. Immunol.* 20, 163–172 (2019).
- 825 26. G. Monaco, B. Lee, W. Xu, S. Mustafah, Y. Y. Hwang, C. Carré, N. Burdin, L.
 826 Visan, M. Ceccarelli, M. Poidinger, A. Zippelius, J. Pedro de Magalhães, A. Larbi,
 827 RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute
 828 Deconvolution of Human Immune Cell Types. *Cell Rep.* 26, 1627-1640.e7 (2019).
- P. Schaerli, K. Willimann, A. B. Lang, M. Lipp, P. Loetscher, B. Moser, CXC
 chemokine receptor 5 expression defines follicular homing T cells with B cell helper
 function. *J. Exp. Med.* **192**, 1553–1562 (2000).
- 28. D. Yu, S. Rao, L. M. Tsai, S. K. Lee, Y. He, E. L. Sutcliffe, M. Srivastava, M.
 Linterman, L. Zheng, N. Simpson, J. I. Ellyard, I. A. Parish, C. S. Ma, Q.-J. Li, C. R.
 Parish, C. R. Mackay, C. G. Vinuesa, The transcriptional repressor Bcl-6 directs T
 follicular helper cell lineage commitment. *Immunity*. **31**, 457–468 (2009).
- Y. S. Choi, R. Kageyama, D. Eto, T. C. Escobar, R. J. Johnston, L. Monticelli, C.
 Lao, S. Crotty, ICOS receptor instructs T follicular helper cell versus effector cell
 differentiation via induction of the transcriptional repressor Bcl6. *Immunity*. 34, 932–
 946 (2011).
- 30. W. Xu, X. Zhao, X. Wang, H. Feng, M. Gou, W. Jin, X. Wang, X. Liu, C. Dong, The
 Transcription Factor Tox2 Drives T Follicular Helper Cell Development via
 Regulating Chromatin Accessibility. *Immunity*. **51**, 826-839.e5 (2019).

- 31. J. Shi, S. Hou, Q. Fang, X. Liu, X. Liu, H. Qi, PD-1 Controls Follicular T Helper Cell
 Positioning and Function. *Immunity*. 49, 264-274 e4 (2018).
- 32. J. Hu, C. Havenar-Daughton, S. Crotty, Modulation of SAP dependent T:B cell
 interactions as a strategy to improve vaccination. *Curr. Opin. Virol.* 3, 363–370
 (2013).
- 33. A. R. Dvorscek, C. I. McKenzie, M. J. Robinson, Z. Ding, C. Pitt, K. O'Donnell, D.
 Zotos, R. Brink, D. M. Tarlinton, I. Quast, IL-21 has a critical role in establishing
 germinal centers by amplifying early B cell proliferation. *EMBO Rep.* 23, e54677
 (2022).
- 34. C.-H. Yeh, J. Finney, T. Okada, T. Kurosaki, G. Kelsoe, Primary germinal centerresident T follicular helper cells are a physiologically distinct subset of CXCR5hiPD1hi T follicular helper cells. *Immunity*. 55, 272-289.e7 (2022).
- 35. S. T. Kim, J.-Y. Choi, B. Lainez, V. P. Schulz, D. E. Karas, E. D. Baum, J. Setlur, P.
 G. Gallagher, J. Craft, Human Extrafollicular CD4+ Th Cells Help Memory B Cells
 Produce Igs. *J. Immunol.* 201, 1359–1372 (2018).
- 858 36. V. Panneton, B. C. Mindt, Y. Bouklouch, A. Bouchard, S. Mohammaei, J. Chang, N.
 Biamantopoulos, M. Witalis, J. Li, A. Stancescu, J. E. Bradley, T. D. Randall, J. H.
 Fritz, W.-K. Suh, ICOS costimulation is indispensable for the differentiation of T
 follicular regulatory cells. *Life Sci Alliance*. 6 (2023), doi:10.26508/lsa.202201615.
- 862 37. L. Mesin, J. Ersching, G. D. Victora, Germinal Center B Cell Dynamics. *Immunity*.
 863 45, 471–482 (2016).
- 38. C. Lamagna, Y. Hu, A. L. DeFranco, C. A. Lowell, B cell-specific loss of Lyn kinase
 leads to autoimmunity. *J. Immunol.* **192**, 919–928 (2014).
- 39. Y. Wang, R. H. Carter, CD19 regulates B cell maturation, proliferation, and positive
 selection in the FDC zone of murine splenic germinal centers. *Immunity*. 22, 749–
 761 (2005).
- 40. A. Erdei, K. G. Kovács, Z. Nagy-Baló, S. Lukácsi, B. Mácsik-Valent, I. Kurucz, Z.
 Bajtay, New aspects in the regulation of human B cell functions by complement
 receptors CR1, CR2, CR3 and CR4. *Immunol. Lett.* 237, 42–57 (2021).
- 41. M. Meister, M. Papatriantafyllou, V. Nordström, V. Kumar, J. Ludwig, K. O. Lui, A.
 S. Boyd, Z. V. Popovic, T. H. Fleming, G. Moldenhauer, P. P. Nawroth, H.-J.
 Gröne, H. Waldmann, T. Oelert, B. Arnold, Dickkopf-3, a tissue-derived modulator
 of local T-cell responses. *Front. Immunol.* 6, 78 (2015).
- R. J. Johnston, L. Comps-Agrar, J. Hackney, X. Yu, M. Huseni, Y. Yang, S. Park,
 V. Javinal, H. Chiu, B. Irving, D. L. Eaton, J. L. Grogan, The immunoreceptor TIGIT
 regulates antitumor and antiviral CD8(+) T cell effector function. *Cancer Cell.* 26,
 923–937 (2014).

- R. A. Elsner, M. J. Shlomchik, Germinal Center and Extrafollicular B Cell
 Responses in Vaccination, Immunity, and Autoimmunity. *Immunity*. 53, 1136–1150
 (2020).
- 44. S. A. Jenks, K. S. Cashman, E. Zumaquero, U. M. Marigorta, A. V. Patel, X. Wang,
 D. Tomar, M. C. Woodruff, Z. Simon, R. Bugrovsky, E. L. Blalock, C. D. Scharer, C.
 M. Tipton, C. Wei, S. S. Lim, M. Petri, T. B. Niewold, J. H. Anolik, G. Gibson, F. E.H. Lee, J. M. Boss, F. E. Lund, I. Sanz, Distinct Effector B Cells Induced by
 Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic
 Lupus Erythematosus. *Immunity*. 49, 725-739.e6 (2018).
- 45. I. Sanz, C. Wei, S. A. Jenks, K. S. Cashman, C. Tipton, M. C. Woodruff, J. Hom, F.
 E.-H. Lee, Challenges and Opportunities for Consistent Classification of Human B
 Cell and Plasma Cell Populations. *Front. Immunol.* **10**, 2458 (2019).
- 46. D. Morgan, V. Tergaonkar, Unraveling B cell trajectories at single cell resolution.
 Trends Immunol. 43, 210–229 (2022).
- P. Milpied, I. Cervera-Marzal, M.-L. Mollichella, B. Tesson, G. Brisou, A. TraverseGlehen, G. Salles, L. Spinelli, B. Nadel, Human germinal center transcriptional
 programs are de-synchronized in B cell lymphoma. *Nat. Immunol.* **19**, 1013–1024
 (2018).
- R. Browaeys, W. Saelens, Y. Saeys, NicheNet: modeling intercellular
 communication by linking ligands to target genes. *Nat. Methods.* **17**, 159–162
 (2020).
- 901 49. G. D. Victora, M. C. Nussenzweig, Germinal Centers. *Annu. Rev. Immunol.* 40, 413–442 (2022).
- 50. A. Biram, N. Davidzohn, Z. Shulman, T cell interactions with B cells during germinal center formation, a three-step model. *Immunol. Rev.* **288**, 37–48 (2019).
- 51. K. L. Good-Jacobson, E. Song, S. Anderson, A. H. Sharpe, M. J. Shlomchik, CD80
 expression on B cells regulates murine T follicular helper development, germinal
 center B cell survival, and plasma cell generation. *J. Immunol.* 188, 4217–4225
 (2012).
- 809 52. R. Browaeys, J. Gilis, C. Sang-Aram, P. De Bleser, L. Hoste, S. Tavernier, D. Lambrechts, R. Seurinck, Y. Saeys, MultiNicheNet: a flexible framework for
 910 differential cell-cell communication analysis from multi-sample multi-condition
 912 single-cell transcriptomics data. *bioRxiv* (2023), p. 2023.06.13.544751, ,
 913 doi:10.1101/2023.06.13.544751.
- 53. N. Giovannone, L. K. Smith, B. Treanor, C. J. Dimitroff, Galectin-Glycan
 Interactions as Regulators of B Cell Immunity. *Front. Immunol.* 9, 2839 (2018).

- 54. M. A. Linterman, W. Pierson, S. K. Lee, A. Kallies, S. Kawamoto, T. F. Rayner, M.
 Srivastava, D. P. Divekar, L. Beaton, J. J. Hogan, S. Fagarasan, A. Liston, K. G. C.
 Smith, C. G. Vinuesa, Foxp3+ follicular regulatory T cells control the germinal
 center response. *Nat. Med.* 17, 975–982 (2011).
- 55. V. R. Fonseca, F. Ribeiro, L. Graca, T follicular regulatory (Tfr) cells: Dissecting the
 complexity of Tfr-cell compartments. *Immunol. Rev.* 288, 112–127 (2019).
- 56. A. Naji, C. Menier, F. Morandi, S. Agaugué, G. Maki, E. Ferretti, S. Bruel, V.
 Pistoia, E. D. Carosella, N. Rouas-Freiss, Binding of HLA-G to ITIM-bearing Ig-like
 transcript 2 receptor suppresses B cell responses. *J. Immunol.* **192**, 1536–1546
 (2014).
- 57. W. Saelens, R. Cannoodt, H. Todorov, Y. Saeys, A comparison of single-cell
 trajectory inference methods. *Nat. Biotechnol.* 37, 547–554 (2019).
- 58. C. Le Coz, D. A. Oldridge, R. S. Herati, N. De Luna, J. Garifallou, E. Cruz Cabrera,
 J. P. Belman, D. Pueschl, L. V. Silva, A. V. C. Knox, W. Reid, S. Yoon, K. B. Zur, S.
 D. Handler, H. Hakonarson, E. J. Wherry, M. Gonzalez, N. Romberg, Human T
 follicular helper clones seed the germinal center-resident regulatory pool. *Sci Immunol.* 8, eade8162 (2023).
- 59. L. Pyöriä, D. Pratas, M. Toppinen, K. Hedman, A. Sajantila, M. F. Perdomo,
 Unmasking the tissue-resident eukaryotic DNA virome in humans. *Nucleic Acids Res.* 51, 3223–3239 (2023).
- 936 60. M. Stano, G. Beke, L. Klucar, viruSITE—integrated database for viral genomics.
 937 Database . 2016, baw162 (2016).
- 61. E. W. Sayers, E. E. Bolton, J. R. Brister, K. Canese, J. Chan, D. C. Comeau, R.
 Connor, K. Funk, C. Kelly, S. Kim, T. Madej, A. Marchler-Bauer, C. Lanczycki, S.
 Lathrop, Z. Lu, F. Thibaud-Nissen, T. Murphy, L. Phan, Y. Skripchenko, T. Tse, J.
 Wang, R. Williams, B. W. Trawick, K. D. Pruitt, S. T. Sherry, Database resources of
 the national center for biotechnology information. *Nucleic Acids Res.* 50, D20–D26
 (2022).
- 944 62. J. Chen, D. Yin, H. Y. H. Wong, X. Duan, K. H. O. Yu, J. W. K. Ho, Vulture: Cloud945 enabled scalable mining of microbial reads in public scRNA-seq data. *bioRxiv*946 (2023), p. 2023.02.13.528411, , doi:10.1101/2023.02.13.528411.
- 63. E. Jokinen, J. Huuhtanen, S. Mustjoki, M. Heinonen, H. Lähdesmäki, Predicting
 recognition between T cell receptors and epitopes with TCRGP. *PLoS Comput. Biol.* 17, e1008814 (2021).
- 950 64. D. Schafflick, C. A. Xu, M. Hartlehnert, M. Cole, A. Schulte-Mecklenbeck, T.
 951 Lautwein, J. Wolbert, M. Heming, S. G. Meuth, T. Kuhlmann, C. C. Gross, H.
 952 Wiendl, N. Yosef, G. Meyer Zu Horste, Integrated single cell analysis of blood and
 953 cerebrospinal fluid leukocytes in multiple sclerosis. *Nat. Commun.* **11**, 247 (2020).

- 65. F. Ingelfinger, L. A. Gerdes, V. Kavaka, S. Krishnarajah, E. Friebel, E. Galli, P.
 Zwicky, R. Furrer, C. Peukert, C.-A. Dutertre, K. M. Eglseer, F. Ginhoux, A. FlierlHecht, T. Kümpfel, D. De Feo, B. Schreiner, S. Mundt, M. Kerschensteiner, R.
 Hohlfeld, E. Beltrán, B. Becher, Twin study reveals non-heritable immune
 perturbations in multiple sclerosis. *Nature*. 603, 152–158 (2022).
- 66. A. Ramesh, R. D. Schubert, A. L. Greenfield, R. Dandekar, R. Loudermilk, J. J.
 Sabatino Jr, M. T. Koelzer, E. B. Tran, K. Koshal, K. Kim, A.-K. Pröbstel, D. Banerji,
 University of California, San Francisco MS-EPIC Team, C.-Y. Guo, A. J. Green, R.
 M. Bove, J. L. DeRisi, J. M. Gelfand, B. A. C. Cree, S. S. Zamvil, S. E. Baranzini, S.
 L. Hauser, M. R. Wilson, A pathogenic and clonally expanded B cell transcriptome
 in active multiple sclerosis. *Proc. Natl. Acad. Sci. U. S. A.* 117, 22932–22943
 (2020).
- 966 67. J. Leffler, S. Trend, N. C. Ward, G. E. Grau, S. Hawke, S. N. Byrne, A. G.
 967 Kermode, M. A. French, P. H. Hart, Circulating Memory B Cells in Early Multiple
 968 Sclerosis Exhibit Increased IgA+ Cells, Globally Decreased BAFF-R Expression
 969 and an EBV-Related IgM+ Cell Signature. *Front. Immunol.* 13, 812317 (2022).
- 88. R. Shinnakasu, T. Inoue, K. Kometani, S. Moriyama, Y. Adachi, M. Nakayama, Y.
 71 Takahashi, H. Fukuyama, T. Okada, T. Kurosaki, Regulated selection of germinal72 center cells into the memory B cell compartment. *Nat. Immunol.* **17**, 861–869
 73 (2016).
- 69. T. Arulraj, S. C. Binder, M. Meyer-Hermann, Investigating the Mechanism of Germinal Center Shutdown. *Front. Immunol.* **13**, 922318 (2022).
- P76
 P77
 P77
- 978 71. B. Serafini, B. Rosicarelli, D. Franciotta, R. Magliozzi, R. Reynolds, P. Cinque, L.
 979 Andreoni, P. Trivedi, M. Salvetti, A. Faggioni, F. Aloisi, Dysregulated Epstein-Barr
 980 virus infection in the multiple sclerosis brain. *J. Exp. Med.* 204, 2899–2912 (2007).
- 72. S. N. Willis, C. Stadelmann, S. J. Rodig, T. Caron, S. Gattenloehner, S. S. Mallozzi,
 J. E. Roughan, S. E. Almendinger, M. M. Blewett, W. Brück, D. A. Hafler, K. C.
 O'Connor, Epstein-Barr virus infection is not a characteristic feature of multiple
 sclerosis brain. *Brain*. **132**, 3318–3328 (2009).
- 73. L. A. N. Peferoen, F. Lamers, L. N. R. Lodder, W. H. Gerritsen, I. Huitinga, J.
 Melief, G. Giovannoni, U. Meier, R. Q. Hintzen, G. M. G. M. Verjans, G. P. van
 Nierop, W. Vos, R. M. B. Peferoen-Baert, J. M. Middeldorp, P. van der Valk, S.
 Amor, Epstein Barr virus is not a characteristic feature in the central nervous
 system in established multiple sclerosis. *Brain*. **133** (2010), p. e137.
- 74. I. Jelcic, F. Al Nimer, J. Wang, V. Lentsch, R. Planas, I. Jelcic, A. Madjovski, S.
 Ruhrmann, W. Faigle, K. Frauenknecht, C. Pinilla, R. Santos, C. Hammer, Y. Ortiz,
 L. Opitz, H. Grönlund, G. Rogler, O. Boyman, R. Reynolds, A. Lutterotti, M.

- Khademi, T. Olsson, F. Piehl, M. Sospedra, R. Martin, Memory B Cells Activate
 Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. *Cell.* **175**, 85100.e23 (2018).
- 996 75. J. Wang, I. Jelcic, L. Mühlenbruch, V. Haunerdinger, N. C. Toussaint, Y. Zhao, C.
 997 Cruciani, W. Faigle, R. Naghavian, M. Foege, T. M. C. Binder, T. Eiermann, L.
 998 Opitz, L. Fuentes-Font, R. Reynolds, W. W. Kwok, J. T. Nguyen, J.-H. Lee, A.
 999 Lutterotti, C. Münz, H.-G. Rammensee, M. Hauri-Hohl, M. Sospedra, S. Stevanovic,
 1000 R. Martin, HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in
 1001 Multiple Sclerosis. *Cell.* 183, 1264-1281.e20 (2020).
- 76. R. M. Gieß, C. Pfuhl, J. R. Behrens, L. Rasche, E. Freitag, N. Khalighy, C. Otto, J.
 Wuerfel, A. U. Brandt, J. Hofmann, B. Eberspächer, J. Bellmann-Strobl, F. Paul, K.
 Ruprecht, Epstein-Barr virus antibodies in serum and DNA load in saliva are not
 associated with radiological or clinical disease activity in patients with early multiple
 sclerosis. *PLoS One.* **12**, e0175279 (2017).
- 1007 77. C. Yea, R. Tellier, P. Chong, G. Westmacott, R. A. Marrie, A. Bar-Or, B. Banwell,
 1008 Canadian Pediatric Demyelinating Disease Network, Epstein-Barr virus in oral
 1009 shedding of children with multiple sclerosis. *Neurology*. 81, 1392–1399 (2013).
- T. M. Yamawaki, D. R. Lu, D. C. Ellwanger, D. Bhatt, P. Manzanillo, V. Arias, H.
 Zhou, O. K. Yoon, O. Homann, S. Wang, C.-M. Li, Systematic comparison of highthroughput single-cell RNA-seq methods for immune cell profiling. *BMC Genomics*.
 22, 66 (2021).
- 1014 79. Ø. Torkildsen, H. Nyland, H. Myrmel, K.-M. Myhr, Epstein-Barr virus reactivation 1015 and multiple sclerosis. *Eur. J. Neurol.* **15**, 106–108 (2008).
- T. Schneider-Hohendorf, L. A. Gerdes, B. Pignolet, R. Gittelman, P. Ostkamp, F. Rubelt, C. Raposo, B. Tackenberg, M. Riepenhausen, C. Janoschka, C. Wünsch, F. Bucciarelli, A. Flierl-Hecht, E. Beltrán, T. Kümpfel, K. Anslinger, C. C. Gross, H. Chapman, I. Kaplan, D. Brassat, H. Wekerle, M. Kerschensteiner, L. Klotz, J. D. Lünemann, R. Hohlfeld, R. Liblau, H. Wiendl, N. Schwab, Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis. *J. Exp. Med.* 219 (2022), doi:10.1084/jem.20220650.
- 1023 81. E. D. SoRelle, N. M. Reinoso-Vizcaino, G. Q. Horn, M. A. Luftig, Epstein-Barr virus 1024 perpetuates B cell germinal center dynamics and generation of autoimmune-1025 associated phenotypes in vitro. *Front. Immunol.* **13**, 1001145 (2022).
- 1026 82. A. J. Thompson, B. L. Banwell, F. Barkhof, W. M. Carroll, T. Coetzee, G. Comi, J.
 1027 Correale, F. Fazekas, M. Filippi, M. S. Freedman, K. Fujihara, S. L. Galetta, H. P.
 1028 Hartung, L. Kappos, F. D. Lublin, R. A. Marrie, A. E. Miller, D. H. Miller, X.
 1029 Montalban, E. M. Mowry, P. S. Sorensen, M. Tintoré, A. L. Traboulsee, M. Trojano,
 1030 B. M. J. Uitdehaag, S. Vukusic, E. Waubant, B. G. Weinshenker, S. C. Reingold, J.
 1031 A. Cohen, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
 1032 Lancet Neurol. 17, 162–173 (2018).

- 83. C. H. Polman, S. C. Reingold, B. Banwell, M. Clanet, J. A. Cohen, M. Filippi, K.
 Fujihara, E. Havrdova, M. Hutchinson, L. Kappos, F. D. Lublin, X. Montalban, P.
 O'Connor, M. Sandberg-Wollheim, A. J. Thompson, E. Waubant, B. Weinshenker,
 J. S. Wolinsky, Diagnostic criteria for multiple sclerosis: 2010 revisions to the
 McDonald criteria. *Ann. Neurol.* 69, 292–302 (2011).
- 84. J. S. Turner, J. Q. Zhou, J. Han, A. J. Schmitz, A. A. Rizk, W. B. Alsoussi, T. Lei, M. Amor, K. M. McIntire, P. Meade, S. Strohmeier, R. I. Brent, S. T. Richey, A. Haile, Y. R. Yang, M. K. Klebert, T. Suessen, S. Teefey, R. M. Presti, F. Krammer, S. H. Kleinstein, A. B. Ward, A. H. Ellebedy, Human germinal centres engage memory and naive B cells after influenza vaccination. *Nature*. 586, 127–132 (2020).
- 1043 85. J. W. Squair, M. Gautier, C. Kathe, M. A. Anderson, N. D. James, T. H. Hutson, R.
 1044 Hudelle, T. Qaiser, K. J. E. Matson, Q. Barraud, A. J. Levine, G. La Manno, M. A.
 1045 Skinnider, G. Courtine, Confronting false discoveries in single-cell differential
 1046 expression. *Nat. Commun.* **12**, 5692 (2021).
- 1047 86. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 87. S. Draghici, P. Khatri, A. L. Tarca, K. Amin, A. Done, C. Voichita, C. Georgescu, R.
 Romero, A systems biology approach for pathway level analysis. *Genome Res.* 17, 1537–1545 (2007).
- 1052 88. C. Voichita, M. Donato, S. Draghici, "Incorporating Gene Significance in the Impact
 1053 Analysis of Signaling Pathways" in 2012 11th International Conference on Machine
 1054 Learning and Applications (2012), vol. 1, pp. 126–131.
- 1055 89. N. Borcherding, N. L. Bormann, G. Kraus, scRepertoire: An R-based toolkit for 1056 single-cell immune receptor analysis. *F1000Res.* **9**, 47 (2020).
- 90. M. Shugay, D. V. Bagaev, I. V. Zvyagin, R. M. Vroomans, J. C. Crawford, G.
 Dolton, E. A. Komech, A. L. Sycheva, A. E. Koneva, E. S. Egorov, A. V. Eliseev, E.
 Van Dyk, P. Dash, M. Attaf, C. Rius, K. Ladell, J. E. McLaren, K. K. Matthews, E. B.
 Clemens, D. C. Douek, F. Luciani, D. van Baarle, K. Kedzierska, C. Kesmir, P. G.
 Thomas, D. A. Price, A. K. Sewell, D. M. Chudakov, VDJdb: a curated database of
 T-cell receptor sequences with known antigen specificity. *Nucleic Acids Res.* 46,
 D419–D427 (2018).
- 1064 91. K. Mayer-Blackwell, S. Schattgen, L. Cohen-Lavi, J. C. Crawford, A. Souquette, J.
 1065 A. Gaevert, T. Hertz, P. G. Thomas, P. Bradley, A. Fiore-Gartland, TCR meta1066 clonotypes for biomarker discovery with tcrdist3 enabled identification of public,
 1067 HLA-restricted clusters of SARS-CoV-2 TCRs. *Elife*. **10**, e68605 (2021).
- 1068 92. R. Orenbuch, I. Filip, D. Comito, J. Shaman, I. Pe'er, R. Rabadan, arcasHLA: high-1069 resolution HLA typing from RNAseq. *Bioinformatics*. **36**, 33–40 (2020).

- 1070 93. B. D. Solomon, H. Zheng, L. W. Dillon, J. D. Goldman, C. S. Hourigan, J. R. Heath,
 1071 P. Khatri, Prediction of HLA genotypes from single-cell transcriptome data. *Front.*1072 *Immunol.* 14, 1146826 (2023).
- 1073 94. D. Pratas, M. Toppinen, L. Pyöriä, K. Hedman, A. Sajantila, M. F. Perdomo, A
 1074 hybrid pipeline for reconstruction and analysis of viral genomes at multi-organ level.
 1075 *Gigascience*. 9 (2020), doi:10.1093/gigascience/giaa086.
- 1076 95. D. Pratas, M. Hosseini, G. Grilo, A. J. Pinho, R. M. Silva, T. Caetano, J. Carneiro,
 1077 F. Pereira, Metagenomic Composition Analysis of an Ancient Sequenced Polar
 1078 Bear Jawbone from Svalbard. *Genes*. 9 (2018), doi:10.3390/genes9090445.
- 1079 96. H. Li, R. Durbin, Fast and accurate long-read alignment with Burrows-Wheeler
 1080 transform. *Bioinformatics*. 26, 589–595 (2010).
- 97. H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G.
 Abecasis, R. Durbin, 1000 Genome Project Data Processing Subgroup, The
 Sequence Alignment/Map format and SAMtools. *Bioinformatics*. 25, 2078–2079
 (2009).
- 1085 98. H. Li, A statistical framework for SNP calling, mutation discovery, association
 1086 mapping and population genetical parameter estimation from sequencing data.
 1087 Bioinformatics. 27, 2987–2993 (2011).
- 1088 99. A. R. Quinlan, *Curr. Protoc. Bioinformatics*, in press.
- 1089
 100. L. Pyöriä, M. Jokinen, M. Toppinen, H. Salminen, T. Vuorinen, V.
 1090
 Hukkanen, C. Schmotz, E. Elbasani, P. M. Ojala, K. Hedman, H. Välimaa, M. F.
 1091
 Perdomo, HERQ-9 Is a New Multiplex PCR for Differentiation and Quantification of
 1092
 All Nine Human Herpesviruses. *mSphere*. 5 (2020), doi:10.1128/mSphere.002651093
- 1094
 101. L. Pyöriä, M. Toppinen, E. Mäntylä, L. Hedman, L.-M. Aaltonen, M. Vihinen1095
 Ranta, T. Ilmarinen, M. Söderlund-Venermo, K. Hedman, M. F. Perdomo, Extinct
 1096
 type of human parvovirus B19 persists in tonsillar B cells. *Nat. Commun.* 8, 14930
 1097
 (2017).

1099 Acknowledgments:

- 1100 We are grateful for the patients and healthy controls for their participation, and without
- 1101 whom this study would not have been possible. We thank Marjo Rissanen and Kalla-
- 1102 Maria Tiilikainen for their help with sample processing. The authors would like to thank
- 1103 the FIMM Single-Cell Analytics unit supported by HiLIFE and Biocenter Finland for
- 1104 scRNA and CITE-seq services.
- 1105

1106 Funding:

- 1107 Academy of Finland grant 332186 (SML)
- 1108 Competitive Research Funding of the State of Finland governed through Helsinki
- 1109 University Hospital grant TYH2020317 (SML)
- 1110 Finska Läkaresällskapet (SML)
- 1111 Suomen MS-Säätiö (JS)
- 1112 Emil Aaltonen Foundation (JS)
- 1113 Instrumentarium Science Foundation (JS)
- 1114 Suomen Lääketieteen säätiö grant 6006 (MP)
- 1115 Liv och Hälsa (MP)
- 1116
- 1117 Author contributions:
- 1118 Conceptualization: SML, JS, MP, EK, PJT
- 1119 Methodology: JS, DY, SML
- 1120 Software: DY, JH
- 1121 Validation: JS, DY, MP
- 1122 Formal Analysis: JS, DY, NK, PD, JH, MP
- 1123 Investigation: JS, PD, KN, GK, RL, MP, SML
- 1124 Resources: SML, MS, EK, MP
- 1125 Data Curation: JS, DY, NK, PD, KN, MP
- 1126 Writing Original Draft: JS, DY, NK, SML
- 1127 Writing Review & Editing: SML, JS, DY, JH, KN, PJT, EK, MP
- 1128 Visualization: JS, DY, NK, JH
- 1129 Supervision: EK, SML

- 1130 Project administration: JS, SML
- 1131 Funding acquisition: SML, EK, MP
- 1132

1133 Competing interests:

- 1134 SML: lecture fees Argenx, Biogen, Janssen, Merck, Novartis, Roche; congress
- 1135 expenses Merck, Novartis; advisory fee Argenx, Novartis, Roche, Sanofi, UCB Pharma;
- 1136 investigator for the clinical study Clarion (Merck) and sub-investigator for the clinical
- 1137 study Fenhance (Roche)
- 1138 PJT: Congress expenses Biogen, Novartis, Merck KGaA, Teva; fees for lectures
- 1139 Biogen, Roche, Novartis, Sanofi-Genzyme, Merck, Teva, Orion, Santen, Alexion.
- 1140

1141 Data and materials availability:

- 1142 The Seurat-objects of the processed scRNA-sequencing data including TCR and BCR
- and CITE-seq data are available at Zenodo (10.5281/zenodo.10006020) with restricted
- access due to GDPR regulations and data can be accessed by placing a request via
- 1145 Zenodo. Differentially expressed gene sets are available in supplementary data files.
- 1146 The reconstructed near-complete HHV-7 genomes are available at GenBank
- 1147 (OR634979 and OR634980). The code to reproduce the key findings is available on
- 1148 GitHub (https://github.com/SarkkinenJ/cervical_lymphnodes_MS.git).
- 1149

Α.



Fig. 1. Skewed B and T cell populations in MS dcLNs highlighting enlarged memory B cell compartment

1154 (A) Schematic diagram of study design, where the left panel illustrates sample collection 1155 including ultrasound-guided fine-needle aspirations (FNA) of deep cervical lymph nodes 1156 (dcLN). The right panel summarizes experiments performed for each subject. (B) 1157 Uniform Manifold Approximation and Projection (UMAP) of identified dcLN scRNA-seq 1158 cell clusters do not show a significant batch effect. (C) UMAP of identified cell clusters 1159 based on a combination of automatic annotation with SingleR (the Monaco reference) 1160 and manual annotation (in-house expertise) aided by the CITE-seq data. (D-E) Dotplot 1161 of key scRNA-seq (D) and CITE-seq (E) marker expression profiles in identified T and B 1162 cell subsets. (F) Bar plot of dcLN cell type proportions. (G) Box plot of cell type 1163 proportions in MS patients compared to controls using an unpaired t-test (p-values < 0.1 1164 are shown). The MS patient with an active relapse is highlighted with a triangle. (H) Bar 1165 plot of standardized Pearson residuals of cell subset numbers using Chi-squared test. 1166 Increased (red) and decreased (blue) cell subsets in MS patients' dcLNs are highlighted 1167 compared to healthy controls. Dashed red lines at ± 3.65 correspond to Bonferroni 1168 corrected p-values (< 0.00013) in the null distribution of standardized residuals. 1169 Abbreviations: GC, Germinal center; NK, Natural killer; PB, plasmablast; Tfh, T follicular 1170 helper, Tfr, T follicular regulator; T reg, regulatory T cell.



Fig. 2. Further analysis of the B cell compartment in MS dcLNs shows increaseddouble negative B cells

1175 (A) UMAP of further clustered naïve and memory B cells. (B) Violin plot presenting the 1176 expression of key transcripts used to identify naïve, switched memory (SM: IgD-, 1177 CD27+), unswitched memory (USM; IgD+, CD27+), and double negative (DN) B cells. (C) Box plot of memory and naïve B cell subsets (% of all B cells in a sample) between 1178 1179 MS patients compared to controls. (D) UMAP of further clustered GC B cells. (E) S (upper panel) and G2M (lower panel) scores of GC B cell clusters were obtained using 1180 1181 Seurat. (F) Violin plot presenting the expression of key transcripts used to identify GC B 1182 cell subsets: light zone (LZ), dark zone (DZ.1, DZ.2), and undefined GC B cell cluster (GC.B). CD3D expression highlights proliferative T cells (prolif.T). (G) Box plot of GC B 1183 1184 cell subsets (% of all GC B cells in the sample) between MS patients and controls. In 1185 (C) and (G), an unpaired t-test was used (p-values < 0.05 are shown), and the patient 1186 with an active relapse is highlighted with a triangle.



1188 Fig. 3. GC BCRs in MS dcLNs are less clonal

1189 (A) Mushroom plot showing intercellular communication of helper T and Tfr cells

- 1190 (ligand) between naïve, memory GC B cells and plasmablasts (receptor) using
- 1191 NicheNet. The colour of red and blue corresponds to the scaled mean (from 0-1)
- 1192 expression of ligand/receptor, while the size of the circle corresponds to a percentage of
- 1193 cells expressing a particular transcript. Red rectangles highlight intercellular
- 1194 communications emphasized in the Results. Diversity of (B) all BCRs, (C) BCRs of GC
- 1195 B cells, and (D) all TCRs presented by boxplots from two different metrics of measuring

- 1196 repertoire diversity: normalized Shannon entropy (0 corresponds to monoclonal
- 1197 BCRs/TCRs, and 1 corresponds to all BCRs/TCRs would be diverse) and percent of
- 1198 unique clonotypes. In each case, an unpaired t-test was used to compare diversity
- 1199 estimates between MS patients and controls (p-values < 0.1 are shown with p-values <
- 1200 0.05 and < 0.1 considered significant and marginally significant respectively).
- 1201



Fig. 4. EBV, HHV-6B and HHV-7 show higher breadth coverage in dcLNs and EBV viral load is increased in MS patients compared to controls

1205 (A) Heatmap illustrates the presence and the percentage of viral reads covering the 1206 EBV, HHV-6B, HHV-7, B19V, and MCPyV reference sequences (breadth coverage) in 1207 dcLNs determined using hybrid-capture sequencing. Viral breadth coverages were 1208 normalized from 0 to 1 separately for each virus, followed by agglomerative hierarchical 1209 clustering using Euclidean distance and Ward.D2 linkage. Dendrograms show the 1210 clustering of samples based on the breadth coverage profiles of the above-tested 1211 viruses. Negative samples for tested viruses are presented in white. (B) Box plot of EBV 1212 copies per 1 million cells in the saliva of MS patients compared to controls. EBV copy 1213 numbers were determined using qPCR. An unpaired t-test was used, and the patient 1214 with an active relapse is highlighted with a triangle.



Fig. 5. MS patient with an active relapse exhibits altered follicular cell ratios and clonally expanded EBV targeting CD8+ T cells

1219 (A) Box plots of GC Tfh / Tfh-like (left) and Tfh / Tfr ratios (right) in the MS patients 1220 compared to healthy controls. Tfh is a sum of Tfh-like and GC Tfh cell counts. (B) Bar 1221 plot of standardized Pearson residuals of cell subset numbers between controls and MS 1222 patients without the patient with a relapse using Chi-squared test. Increased (red) and 1223 decreased (blue) cell subsets in MS patients compared to healthy controls are 1224 highlighted. Dashed red lines at ± 3.65 correspond to Bonferroni corrected p-values (< 1225 0.00013) in the null distribution of standardized residuals. (C) Box plots of plasmablast 1226 (left) and GC B cell (right) BCR richness (BCRs of total BCR clonotypes in each 1227 sample). (D) Box plot of expanded T cell clonotypes of all T cell clones (%) in each 1228 sample. (E) Stacked bar plot of predicted specificity in expanded T cell clonotypes. The

- 1229 VDJdb database was scanned for TCRab and b clonotypes using tcrdist3. In A and C-E,
- 1230 the patient with an active relapse is highlighted with a triangle.

1232	Table 1: Characteristics of MS patients
1233	

ID	Age	Sex	Other	MS	MRI	Time	Time	Time	LN	EDSS at	EDSS at 1
			diseases	type	Barkhoff	from	from	from	size	sample	year follow up
						onset	last	ivMP	(cm)	collection	
						(months)	relapse	(months)			
MS001	20-	М	asthma,	RRMS	4/4	8	8	-	2,06	0	0
	29		pollen						х		
			allergy						0,63		
MS002	40-	М	no	RRMS	4/4	33	3	3	2,00	2.0	1.0
	49								x		
									0,22		
MS003	30-	F	no	RRMS	3/4	4	4	-	NA	0	0
	39										
MS004	30-	F	no	RRMS	3/5	4	4	-	NA	1	1
	40										
MS005	20-	F	asthma,	RRMS	3/4	4	4	-	2.2 x	0	0
	29		migrane,						0.53		
			mild								
			ankylosing								
			spondylitis								
MS006	40-	М	no	RRMS	3/4	75	6	6	NA	1.0	0
	49										
MS007	40-	М	no	RRMS	4/4	36	3	3	1.04	2.5	5.0
	49								х		
									0.58		
MS010	30-	F	no	PPMS	4/4	24	10	12	0.88	6.0	6.0
	39								х		
									0.35		
MS011	30-	М	no	RRMS	4/4	48	0	-	1.85	3.5	2.0
	39								Х		
									0.58		

Abbreviations: ivMP, intravenous methylprednisolone; EDSS, Expanded Disability Status Scale; LN, lymph node

Table 2: Results from the viral assays

		Plasma	Saliva	(copies / cells)	′ 1*10^6	cLN (breadth of coverage in %)					
ID	type	EBV VCA IgG (RU/ml)	EBV	HHV6B	HHV7	EBV	HHV- 6B	HHV- 7	MCPyV	B19V	
CTRL008	CTRL	0	0	82	32400						
CTRL009	CTRL	104,59	387	132	77,1						
CTRL012	CTRL	151	0	0	347	5,13	0	26,4	22.4	89,5	
CTRL013	CTRL	63,5	0	17,9	2210	0	0	3,8	3.4	41,2	
CTRL014	CTRL	137	0	38,2	525						
CTRL015	CTRL	146,3	0	334	25300	0	0	0	0	12,3	
CTRL016	CTRL		0	491	211000	20,8	0	11,4	0	8,4	
MS001	MS	172,86	3270	33,8	2030						
MS002	MS	136,26	52,8	314	375	29,9	0	36,8	3,5	6,2	
MS003	MS	179,04	0	69,2	11800	28,2	0	1,84	0	3,1	
MS004	MS	223,73	26,2	297	3680	14,7	10,12	98,6	0	0	
MS005	MS	194,59	17000	219	74100	0	9,5	95,67	6,7	3,5	
MS006	MS	179,72	4520	0	221						
MS007	MS	209,72	10,4	15,2	2350						
MS010	MS	153,48	37	0	1890						
MS011	MS	177,19	6660	389	154000						

Abbreviations: EBV, Epstein-Barr Virus; HHV, human herpes virus; MCPyV, Merkel cell polyomavirus; B19V, parvovirus B19